SCHEMBL12901016

SCHEMBL12901016

O=C(Nc1ccc(F)cc1)c1sccc1Nc1ccnc2[nH]ccc12

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ABCB1 P08183 2/20 0.52
FLT1 P17948 2/20 0.52
MET P08581 9/20 0.44
AURKA O14965 1/20 0.43
AURKB Q96GD4 1/20 0.43
JAK2 O60674 1/20 0.42
JAK1 P23458 1/20 0.42
TYK2 P29597 1/20 0.42
TTBK1 Q5TCY1 1/20 0.41
TTBK2 Q6IQ55 1/20 0.41
PKM P14618 1/20 0.41
MEN1 O00255 1/20 0.41
KMT2A Q03164 1/20 0.41
KDM4E B2RXH2 1/20 0.40
ALDH1A1 P00352 1/20 0.40
GLA P06280 1/20 0.40
HPGD P15428 1/20 0.40
KIT P10721 2/20 0.40
KDR P35968 2/20 0.40
EGFR P00533 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12900384 0.89 KDR (0.51) ABCB1FLT1METJAK2JAK1
SCHEMBL12901021 0.88 MET (0.52) METTTBK1TTBK2PKMMEN1
SCHEMBL19371923 0.83 MET (0.45) METAURKAAURKBJAK2JAK1
SCHEMBL12901013 0.83 NPC1 (0.43) JAK2JAK1TYK2ALDH1A1HPGD
SCHEMBL12901017 0.82 SMN1; SMN2 (0.47) JAK2JAK1TYK2PKMMEN1
SCHEMBL1230808 0.81 SENP2 (0.50) AURKAAURKBMEN1KMT2A
SCHEMBL12900383 0.81 KDM4E (0.40) ABCB1FLT1METJAK2JAK1
SCHEMBL1229680 0.81 JAK2 (0.44) FLT1AURKBJAK2JAK1TYK2
SCHEMBL1231319 0.79 JAK2 (0.46) AURKBJAK2JAK1TYK2ROCK2
SCHEMBL1230522 0.79 IKBKB (0.46) AURKBJAK2JAK1TYK2ROCK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2462141-B1 NOVEL AZAHETEROCYCLIC COMPOUNDS MERCK PATENT GMBH (DE) 2017-09-27 EP disclosed
US-9023847-B2 Azaheterocyclic compounds MERCK PATENT GMBH (DE) 2015-05-05 US disclosed
US-20120277228-A1 Novel Azaheterocyclic Compounds MERCK PATENT GMBH (DE) 2012-11-01 US disclosed
WO-2011017009-A1 NOVEL AZAHETEROCYCLIC COMPOUNDS MERCK PATENT GMBH (DE) 2011-02-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120277228-A1 Novel Azaheterocyclic Compounds PCNA, MCL1, MYC ABCB1 998/4885FLT1 996/4885MET 400/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.